Patrick Daugherty is CEO of SerImmune and Adjunct Professor of Chemical Engineering, at the University of California, Santa Barbara. Daugherty received his B.S. in Chemical Engineering from The University of Minnesota in 1993, and his Ph.D. from the University of Texas at Austin in 1999. He was a Research Fellow at the Fred Hutchinson Cancer Research Center in Seattle during 1999-2001, before joining the Chemical Engineering faculty at UCSB in 2001. He is the recipient of a National Sciences Foundation Career Award (2005), Camille Dreyfus Teacher Scholar Award (2006), and the Genentech Young Investigator Award from the ACS Division of Biochemical Technology (2007). Daugherty co-founded CytomX Therapeutics, Inc. (2008) – Nasdaq:CTMX, Cynvenio Biosystems (2008), and SerImmune Inc. (2014). Daugherty was elected to the American Institute of Medical and Biological Engineering (AIMBE) in 2011, honoring the top 2% of bioengineers. Professor Daugherty’s research and current work at SerImmune is focused on the functional characterization of human B-cell and antibody repertoires, to identify environmental factors involved in human disease, discover biomarkers for early and accurate diagnosis, and develop targeted biopharmaceuticals.